Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LDLR | P01130 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28137790 | 0.74 | LTA4H (0.36) | LTA4H | |
| SCHEMBL276781 | 0.74 | LTA4H (0.36) | LTA4H | |
| SCHEMBL6639614 | 0.74 | LTA4H (0.36) | LTA4H | |
| SCHEMBL1535169 | 0.74 | LTA4H (0.36) | LTA4H | |
| SCHEMBL9989711 | 0.69 | LTA4H (0.34) | LTA4H | |
| SCHEMBL2011856 | 0.69 | LTA4H (0.34) | LTA4H | |
| SCHEMBL27990888 | 0.69 | LTA4H (0.45) | LTA4H | |
| SCHEMBL48312 | 0.69 | LTA4H (0.45) | LTA4H | |
| SCHEMBL5675147 | 0.66 | LTA4H (0.43) | LTA4H | |
| SCHEMBL24017983 | 0.65 | LTA4H (0.42) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12571024-B2 | Methods and compositions relating to covalently closed nucleic acids | Twist Bioscience Corporation (US) | 2026-03-10 | — | — | US | claimed |
| EP-4388118-A2 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CLOSED NUCLEIC ACIDS | Twist Bioscience Corporation (US) | 2024-06-26 | — | — | EP | claimed |
| US-20230115861-A1 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CLOSED NUCLEIC ACIDS | Twist Bioscience Corporation | 2023-04-13 | — | — | US | claimed |
| WO-2023023285-A2 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CLOSED NUCLEIC ACIDS | Twist Bioscience Corporation (US) | 2023-02-23 | — | — | WO | claimed |
| US-11390913-B2 | Single primer to dual primer amplicon switching | SIGMA-ALDRICH CO. LLC (US) | 2022-07-19 | — | — | US | claimed |
| EP-3516075-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | Sigma-Aldrich Co., LLC (US) | 2019-07-31 | — | — | EP | claimed |
| US-20190211386-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | SIGMA-ALDRICH CO. LLC | 2019-07-11 | — | — | US | claimed |
| CN-109804083-A | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2019-05-24 | — | — | CN | claimed |
| WO-2018057846-A1 | SINGLE PRIMER TO DUAL PRIMER AMPLICON SWITCHING | SIGMA-ALDRICH CO, LLC (US) | 2018-03-29 | — | — | WO | claimed |
| US-20170369928-A1 | METHOD FOR EVALUATING DNA DAMAGE FROM ANALYTE | Sogang University Research Foundation | 2017-12-28 | — | — | US | claimed |
| WO-2013090873-A1 | A COMPOSITION AND METHOD FOR REDUCING CYANURIC ACID IN RECREATIONAL WATER | HAVILAND PRODUCTS COMPANY (US) | 2013-06-20 | — | — | WO | claimed |
| EP-2601209-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | Bayer Intellectual Property GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016960-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | WO | claimed |
| US-12571024-B2 | Methods and compositions relating to covalently closed nucleic acids | Twist Bioscience Corporation (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4388118-A2 | METHODS AND COMPOSITIONS RELATING TO COVALENTLY CLOSED NUCLEIC ACIDS | Twist Bioscience Corporation (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117512078-A | Single primer to double primer amplicon conversion | 西格马-奥尔德里奇有限责任公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-101648951-A | pentoxifylline derivative | KUI XU | 2010-02-17 | — | — | CN | disclosed |
| US-6090553-A | DETECTING PRESENCE OF SPECIFIC NUCLEIC ACID SEQUENCE IN SAMPLE USING POLYMERASE CHAIN REACTION, CLEAVING AMPLIFIED PRODUCTS WITH BASE EXCISION REPAIR ENZYME, AND DETECTING DNA SEGMENTS BY REVERSE BLOT HYBRIDIZATION | BECKMAN COULTER, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5871992-A | REPAIR OF DNA WITH ENZYME OF GLYCOSYLASE/AP LYASE ALSO FUSION PROTEINS | NEW YORK UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1997031612-A2 | MAMMALIAN ENDONUCLEASE III, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NEW YORK UNIVERSITY (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571024-B2 | Methods and compositions relating to covalently closed nucleic acids | UNG, OGG1, RNGTT | LTA4H 3636/4885LDLR 3674/4885PCSK9 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.